Pseudomonas Infections  >>  ciprofloxacin (Q3939)  >>  Phase 4
Welcome,         Profile    Billing    Logout  

1 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
ciprofloxacin (Q3939) / Bayer, Novartis
NCT00481689: Study To Evaluate The Efficacy And Safety Of Ciprofloxacin Extended-Release (Cipro® XR) 1000 mg Tablets Given Once Daily For 7 To 14 Days In The Treatment Of Patients 18 Years Or Older With Complicated Urinary Tract Infections Caused By Pseudomonas Aeruginosa And Other Common Uropathogens

Completed
4
500
US
Cipro XR (Ciprofloxacin, BAYQ3939)
Bayer
Urinary Tract Infections
 
09/05

Download Options